ADAM9 and neoplasm: We also demonstrated a significant correlation between tumor ADAM9 staining and the risk of prostate cancer recurrence and death in patients who underwent hormone therapy, suggesting that a progressive increase in ADAM9 expression could be used as a biomarker for poor prognosis in prostate cancer patients after hormone therapy [15].